by Janncike Kristoffersen | Jan 5, 2024
Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical studies, and commercial results. When someone is willing to pay for products, services, and values created when knowledge is...
by Janncike Kristoffersen | Jan 16, 2023
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Sep 25, 2020
Inven2 handles agreements for clinical studies on behalf of the Cancer Clinic at Oslo University Hospital for most Norwegian companies that develop cancer treatments. “This is an important contribution to the Norwegian health industry and shows that we are competing...
by Elisabeth Kirkeng Andersen | Aug 16, 2020
Inven2 is 10 years in 2020. ‘I’m proud of what we have achieved over these ten years. I’m particularly proud of the fact that we have contributed to ploughing NOK 500 million back into new research, innovation and to inventors,’ says Ole Kristian Hjelstuen, CEO of...
